Q32 Bio Sells Complement Inhibitor ADX-097 to Akebia Therapeutics for Upfront and Milestone Payments.

Q32 Bio has sold its complement inhibitor ADX-097 to Akebia Therapeutics, securing upfront and milestone payments that extend its cash runway into 2027. The deal includes $12 million in upfront and near-term milestone payments, potential development, regulatory, and commercial milestones totaling up to $592 million, and tiered royalties ranging from low single-digit to mid-teen percentages on future sales. Q32 Bio will focus on advancing its flagship program, bempikibart, for alopecia areata.